Ensysce Biosciences, Inc. (ENSC) vs IMMURON (IMRN)

Ensysce Biosciences, Inc. and IMMURON are both Biotechnology companies. Ensysce Biosciences, Inc. and IMMURON are of similar size ($7.0M and $6.9M). IMMURON grew revenue faster over the last twelve months: −6.62% against −39.3%. IMMURON has the higher net margin (−262.7% vs −280.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, IMMURON leads on 11 and Ensysce Biosciences, Inc. on 3.

Valuation

Metric ENSC IMRN Biotechnology median
P/E n/m n/m 10.60
P/S 0.98 n/m 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.93 0.66
EV/Sales 1.01 (3.47) 9.02
Earnings yield (811.76%) (2.51%) (32.88%)
Free cash flow yield (199.80%) 0.00% (23.13%)

Profitability

Metric ENSC IMRN Biotechnology median
Gross margin 100.00% 71.28% 68.51%
Operating margin (281.32%) 0.00% 0.00%
Net margin (280.49%) (262.71%) 0.00%
Free cash flow margin (196.76%) 0.00% 0.00%
Return on equity (1,295.01%) 0.00% (51.96%)
Return on assets (295.92%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENSC IMRN Biotechnology median
Revenue growth (TTM) (39.29%) (6.62%) 6.76%
EPS growth (last fiscal year) 65.24% 37.29% 29.88%
Revenue growth, 5-year CAGR 5.21% 116.96% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENSC IMRN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.70 7.26 4.97
Net debt to EBITDA 0.42 1.81 1.01

Dividend

Metric ENSC IMRN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENSC IMRN Biotechnology median
Market cap 7.02m 6.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack